Research Article
Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
Table 1
Baseline characteristics of the patients (
).
| | ACEI | ARB | value |
| | Number, (%) | 562 (18.1%) | 2539 (81.9%) | | | Age, years | | | 0.068 | | Female, (%) | | | | | BMI, kg/m2 | | | 0.001 | | BUN, mg/dL | | | <.001 | | Creatinine, mg/dL | | | <.001 | | MDRD-eGFR, mL/min/1.73 m2 | | | <.001 | | MDRD-eGFR, (%) | | | <.001 | | ≥90 mL/min/1.73 m2 | 189 (33.6) | 718 (28.3) | | | 60-89 mL/min/1.73 m2 | 297 (52.9) | 1297 (51.1) | | | <60 mL/min/1.73 m2 | 76 (13.5) | 524 (20.6) | | | Sodium, mEq/L | | | 0.711 | | Potassium, mEq/L | | | 0.009 | | Comorbidity, (%) | | | | | Heart failure | 5 (0.9) | 35 (1.4) | 0.353 | | Hypertensive disease | 29 (5.2) | 133 (5.2) | 0.940 | | Ischemic heart disease | 303 (53.9) | 978 (38.5) | <.001 | | Cerebrovascular disease | 27 (4.8) | 163 (6.4) | 0.148 | | Diabetes mellitus | 36 (6.4) | 133 (5.2) | 0.270 | | Acute renal failure | 7 (1.3) | 109 (4.3) | 0.001 | | Cancer | 43 (7.7) | 274 (10.8) | 0.026 | | Medication, (%) | | | | | β-Blocker | 217 (38.6) | 782 (30.8) | <.001 | | CCB | 161 (28.7) | 1157 (45.6) | <.001 | | Statin | 437 (77.8) | 1565 (61.6) | <.001 |
|
|
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CCB, calcium channel blocker; GFR, glomerular filtration rate, MDRD, modification of diet in renal disease.
|
